ARGX - ARGENX SE
614.76
14.250 2.318%
Share volume: 215,858
Last Updated: 04-25-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
-0.03%
PREVIOUS CLOSE
CHG
CHG%
$600.51
14.25
0.02%
Fundamental analysis
0%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
0%
Performance
5 Days
3.38%
1 Month
4.35%
3 Months
-1.33%
6 Months
-1.33%
1 Year
-1.33%
2 Year
-1.33%
Key data
Stock price
$614.76
DAY RANGE
$594.76 - $616.86
52 WEEK RANGE
$519.70 - $650.79
52 WEEK CHANGE
-$1.33
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-08-2025
Company detail
CEO: Tim v. Hauwermeiren
Region: US
Website: argenx.com
Employees: 650
IPO year: 2017
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing
Region: US
Website: argenx.com
Employees: 650
IPO year: 2017
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases. Its lead product candidate is efgartigimod for the. treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS.
Recent news
